Etid klinik pou Kansè ovè nan Oklahoma
31 etid pou Kansè ovè ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07024784Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT07318558Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- OU Health, Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT05739981FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Aug 26, 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06751329A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekrite
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068Clinical Pre-screening Protocol for Ovarian Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jul 30, 2026 · NCT03877796A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Jul 14, 2026 · NCT04606914A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteVolontè an sante akeyi
Laj 50 a 74 · Fanm · Mizajou May 6, 2026 · NCT00539162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Stephenson Cancer Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 14, 2026 · NCT06234423A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 7, 2026 · NCT06999187CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 5, 2025 · NCT05932862Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.